Vobramitamab duocarmazine

N/A

Report date: 2026/02/10 20:00:22

Base Information

Drug NameVobramitamab duocarmazine
Drug Alias NameDuocarmycin analog-anti-B7-H3 antibody conjugateMGC-018
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > seco-DUBA payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionAnti-CD276DNA inhibitors
TargetsCD276 antigenDNA
Therapy Area/IndicationsOral Squamous Cell CarcinomaHormone-Resistant Prostate NeoplasmsSolid tumours +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesGeorgetown UniversitySynthon Biopharmaceuticals BvMacrogenics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Ovarian Epithelial +[6] 
Inactive IndicationsOral Squamous Cell CarcinomaHormone-Resistant Prostate NeoplasmsProstatic Neoplasms, Castration-Resistant +[9] 

Other Information

ATC CodeN/A
Related LinksN/A